Leflunomide may be associated with an increased risk of interstitial lung disease (ILD) in Korean patients
- PDF / 136,289 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 81 Downloads / 262 Views
1
■ Leflunomide may be associated with an increased risk of interstitial lung disease (ILD) in Korean patients, and "should be used with caution in patients who have preexisting lung disease", say researchers from Korea. To determine whether leflunomide was associated with ILD in Korean patients with rheumatoid arthritis (RA), the researchers analysed data for 1010 such patients (average age 51.5 years) who had received leflunomide 10 or 20 mg/day for ≥ 1 month. Ten patients (1%) developed ILD, six of whom had pre-existing lung disease (p < 0.001). Treatment included initiation of corticosteroids and/or colestyramine, and cessation of leflunomide. There were no fatalities among the patients, "probably due to early diagnosis and prompt intervention", note the researchers. Ju JH, et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis and 801078858 Rheumatism 56: 2094-2096, No. 6, Jun 2007
0114-9954/10/1166-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 25 Aug 2007 No. 1166
Data Loading...
